February 12, 2025

Multiple myeloma: dangerous diversity – healthcare-in-europe.com

February 12, 2025

Opna Bio Receives Orphan Drug Designation for OPN-6602, an Oral EP300/CBP Bromodomain Inhibitor, for Multiple Myeloma

February 12, 2025

Updates in Multiple Myeloma from ASH 2024

Several presentations at the 2024 American Society of Hematology (ASH) Annual Meeting relayed new and updated study data in multiple myeloma (MM), along with significant advancements in the treatment of Smoldering multiple myeloma (SMM) Prognostic indicators Newly diagnosed MM (NDMM) Maintenance therapy Minimal residual disease (MRD) testing Relapsed/refractory MM (RRMM) AL amyloidosis Advances in SMM […]

February 7, 2025

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development – Nature

January 29, 2025

Cilta-cel: A new era in multiple myeloma treatment – Drug Target Review